Skip to main content
×
×
Home

Detection of pegylated epoetin β in horse plasma after intravenous administration

  • D H Catlin (a1), G A Maylin (a2), S Benchaar (a1), S M Neades (a1), M S Timmons (a1) and K H McKeever (a3)...
Abstract

Methoxy polyethylene glycol–epoetin β (pegylated epoetin β, peg-epoetin β, Mircera®) is an erythropoiesis-stimulating agent that is synthesized by pegylating epoetin β. It is prohibited in racehorses and humans because it enhances their performance. It is detectable in human urine and plasma using the isoelectric focusing–double-blotting (IEF–DB) method that has been widely applied in human doping control laboratories to detect doping with recombinant erythropoietins (EPOs). Fifty micrograms of peg-epoetin β were administered intravenously to a 450 kg female Thoroughbred, and blood was collected for 48 h. The plasma was processed by immunopurification followed by IEF–DB. The analytical procedures required about 2 days. No peg-epoetin β was detected in the baseline plasma collected prior to drug administration. It was readily detected in samples collected at 2, 4, 6, 8, 24 and 48 h. The isoforms showed a characteristic pattern that differed from epoetin β and was unlike any other known erythrocyte-stimulating agent or recombinant EPO. No peg-epoetin β was detected in plasma from five control horses. The plasma samples were also tested by a rapid, automated and chemiluminescent immunometric assay for EPO (Immulite®). The samples collected from the treated horse at 2–48 h contained the equivalent of approximately 200–800 pg ml− 1 of peg-epoetin β. The samples from the ten control horses were negative. These data show that a small dose of peg-epoetin β is detectable for 48 h by two different methods that are based on two different principles (chemiluminescence immunoassay and IEF–DB). The Immulite® assay is suitable as a screen and the IEF–DB assay as a confirmation method. These studies need to be expanded to other horses. The screen and confirmation tests, if applied, will probably eliminate the use of peg-epoetin β as a horse doping agent.

Copyright
Corresponding author
*Corresponding author: dcatlin@antidopingresearch.org
References
Hide All
1Ekblom, B (1996). Blood doping and erythropoietin. The effects of variation in hemoglobin concentration and other related factors on physical performance. The American Journal of Sports Medicine 24: S40S42.
2McKeever, KH, Agans, JM, Geiser, S, Lorimer, PJ and Maylin, GA (2006). Low dose exogenous erythropoietin elicits an ergogenic effect in Standardbred horses. Equine Veterinary Journal, Supplement 36: 233238.
3Catlin, DH and Hatton, CK (2009). Abuse of recombinant erthropoietins by athletes. In: Elliott, SG, Foote, MA and Molineux, G (eds) Erythropoietins, Erythropoietic Factors, and Erythropoiesis. Molecular, Cellular, Preclinical, and Clinical Biology. 2nd edn.Basel: Birkhäuser.
4Elliott, S (2008). Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. British Journal of Pharmacology 154: 529541.
5Lasne, F, Martin, L, Martin, JA and de Ceaurriz, J (2009). Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 94: 888890.
6Lasne, F and de Ceaurriz, J (2000). Recombinant erythropoietin in urine. Nature 405: 635.
7Lasne, F, Martin, L, Crepin, N and de Ceaurriz, J (2002). Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Analytical Biochemistry 311: 119126.
8Lasne, F (2001). Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. Journal of Immunological Methods 253: 125131.
9Catlin, DH, Breidbach, A, Elliott, S and Glaspy, J (2002). Comparison of isoelectric focusing patterns of darbepoetin alfa, recombinant human EPO, and endogenous EPO from human urine. Clinical Chemistry 48: 20572059.
10Lasne, F, Popot, MA, Varlet-Marie, E, Martin, L, Martin, JA, Bonnaire, Y, et al. (2005). Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. Journal of Analytical Toxicology 29: 835837.
11Sato, F, Yamashita, S, Kugo, T, Hasegawa, T, Mitsui, I and Kijima-Suda, I (2004). Nucleotide sequence of equine erythropoietin and characterization of region-specific antibodies. American Journal of Veterinary Research 65: 1519.
12Kearns, CF, Lenhart, JA and McKeever, KH (2000). Cross-reactivity between human and erythropoietin antibody and horse erythropoietin. Electrophoresis 21: 14541457.
13Lasne, F, Martin, L, Martin, JA and de Ceaurriz, J (2007). Isoelectric profiles of human erythropoietin are different in serum and urine. International Journal of Biological Macromolecules 41: 354357.
14Lamon, S, Giraud, S, Egli, L, Smolander, J, Jarsch, M, Stubenrauch, KG, et al. (2009). A high-throughput test to detect C.E.R.A. doping in blood. Journal of Pharmaceutical and Biomedical analysis. doi:10.1016/jpba.2009.06.038.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Comparative Exercise Physiology
  • ISSN: 1755-2540
  • EISSN: 1755-2559
  • URL: /core/journals/comparative-exercise-physiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed